Skip to content
My WebMD Sign In, Sign Up

Breast Cancer Health Center

Font Size

New Drugs for Hard-to-Treat Breast Cancer

Study Shows PARP Inhibitors Fight Triple-Negative Breast Cancer

How PARP Inhibitors Work continued...

The new drug was well tolerated, with minimal side effects.

BiPar Sciences Inc., which makes the drug and funded the work, plans to launch a larger study this summer.

In the second study, 54 women with breast cancer that was deficient in BRCA1 or BRCA2 and that persisted despite several rounds of standard chemotherapy were given one of two doses of olaparib. Olaparib is given in pill form, while BSI-201 is injected.

Tumors shrank in 41% of those given the higher dose. The most common side effects were low-grade fatigue and nausea.

Drugmaker AstraZeneca, which funded the work, is in the process of designing a larger study, according to a company spokesperson.

More research is needed, all agree. But if the positive results hold up in future studies, PARP inhibitors will "be a real advance" for women with aggressive, hard-to-treat breast tumors, Winer says.

1|2

Today on WebMD

Breast Cancer Overview
From self-exams and biopsies to reconstruction, we’ve got you covered.
Dealing with breast cancer
Get answers to your questions.
 
woman having mammogram
Experts don’t agree on all fronts, but you can be your own advocate.
woman undergoing breast cancer test
Many women worry. But the truth? Most abnormalities aren’t breast cancer.
 
Breast Cancer Treatments Improving
VIDEO
Resolved To Quit Smoking
SLIDESHOW
 
Woman getting mammogram
Article
Screening Tests for Women
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
serious woman
Article
 
what is your cancer risk
HEALTH CHECK
10 Ways to Revitalize Slideshow
SLIDESHOW